Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: A GELA study

Blood

Volumn 116, Issue 7, 2010, Pages 1092-1104

  Jardin, Fabrice ^a   Jais, Jean Philippe ^b   Molina, Thierry Jo ^c   Parmentier, Françoise ^a   Picquenot, Jean Michel ^a   Ruminy, Philippe ^a   Tilly, Hervé ^a   Bastard, Christian ^a   Salles, Gilles André ^d   Feugier, Pierre ^e   Thieblemont, Catherine ^f   Gisselbrecht, Christian ^f   De Reynies, Aurelien ^g   Coiffier, Bertrand ^d   Haioun, Corinne ^h   Leroy, Karen ^h,i  

^a UNIVERSITÉ DE ROUEN   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HÔTEL DIEU   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e CHU NANCY BRABOIS   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g Cartes d'Identité des Tumeurs Program   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ INSERM U955   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RETINOBLASTOMA PROTEIN; RITUXIMAB; TRANSCRIPTION FACTOR E2F; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN BCL 2; PROTEIN P53; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR REL;

ADULT; AGED; ARTICLE; BCL2 GENE; CDKN1B GENE; CDKN2A GENE; CELL METABOLISM; FEMALE; GENE; GENE DOSAGE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; ONCOGENE MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; RB1 GENE; TP53 GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS C-REL; RETINOBLASTOMA PROTEIN; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE; YOUNG ADULT;

EID: 77956553931     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-247122     Document Type: Article

References (45)

1. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5):1851-1861.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
3. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520-13525.
4. Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106(9):3183-3190. (Pubitemid 41565917)
5. Chen W, Houldsworth J, Olshen AB, et al. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood. 2006;107(6):2477-2485. (Pubitemid 43345571)
6. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-721.
7. Ruminy P, Jardin F, Picquenot JM, et al. Two patterns of chromosomal breakpoint locations on the immunoglobulin heavy-chain locus in lymphomas with t(3;14)(q27;q32): relevance to histology. Oncogene. 2006;25(35):4947-4954. (Pubitemid 44201185)
8. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99(7):2285-2290.
9. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
10. Jais JP, Haioun C, Molina TJ, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia. 2008;22(10):1917-1924.
11. Casilli F, Di Rocco ZC, Gad S, et al. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat. 2002;20(3):218-226. (Pubitemid 34966850)
12. Jardin F, Ruminy P, Kerckaert JP, et al. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas. Haematologica. 2008;93(4):543-550. (Pubitemid 351536382)
13. Jardin F, Picquenot JM, Parmentier F, et al. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value. Br J Haematol. 2009;146(6):607-618.
14. Jardin F, Callanan M, Penther D, et al. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia. 2009;23(4):698-707.
15. Bastard C, Raux G, Fruchart C, et al. Comparison of a quantitative PCR method with FISH for the assessment of the four aneuploidies commonly evaluated in CLL patients. Leukemia. 2007;21(7):1460-1463. (Pubitemid 46965287)
16. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-4126.
17. Killian A, Di Fiore F, Le Pessot F, et al. A simple method for the routine detection of somatic quantitative genetic alterations in colorectal cancer. Gastroenterology. 2007;132(2):645-653. (Pubitemid 46298738)
18. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991-9996. (Pubitemid 37087056)
19. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
20. Smyth G, Gordon K. Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments: Statistical Applications in Genetics and Molecular Biology, Vol. 3. Berkeley, CA: Berkeley Electronic Press; 2004.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc B. 1995;57:289-300.
22. Goeman JJ, Buhlmann P. Analyzing gene expression data in terms of gene sets: methodological issues. Bioinformatics. 2007;23(8):980-987. (Pubitemid 47050585)
23. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550. (Pubitemid 41528093)
24. National Center for Biotechnology Information. Gene Expression Omnibus Database. http://www.ncbi.nlm.nih.gov/geo/. Accessed May 2010.
25. Hess A, Iyer H. Fisher's combined p-value for detecting differentially expressed genes using Affymetrix expression arrays. BMC Genomics. 2007;8:96.
26. Young KH, Weisenburger DD, Dave BJ, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007;110(13):4396-4405.
27. Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112(10):4235- 4246.
28. Vernell R, Helin K, Muller H. Identification of target genes of the p16INK4A-pRB-E2F pathway. J Biol Chem. 2003;278(46):46124-46137.
29. Ren B, Cam H, Takahashi Y, et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 2002;16(2):245-256. (Pubitemid 34075816)
30. Aamot HV, Micci F, Holte H, Delabie J, Heim S. G-banding and molecular cytogenetic analyses of marginal zone lymphoma. Br J Haematol. 2005;130(6):890-901. (Pubitemid 43899730)
31. Natkunam Y, Lossos IS, Taidi B, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood. 2005;105(10):3979-3986.
32. Ito Y, Miyauchi A, Yoshida H, et al. Expression of alpha1,6- fucosyltransferase (FUT8) in papillary carcinoma of the thyroid: its linkage to biological aggressiveness and anaplastic transformation. Cancer Lett. 2003;200(2):167-172. (Pubitemid 38366098)
33. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-2430. (Pubitemid 43855045)
34. Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007;21(11):2332-2343. (Pubitemid 350011706)
35. Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165(1):159-166. (Pubitemid 38821823)
36. Young KH, Leroy K, Moller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008;112(8):3088-3098.
37. Rizos H, McKenzie HA, Ayub AL, et al. Physical and functional interaction of the p14ARF tumor suppressor with ribosomes. J Biol Chem. 2006;281 (49):38080-38088. (Pubitemid 46042111)
38. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3(2):185-197.
39. Marce S, Balague O, Colomo L, et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res. 2006;12(12):3754-3761. (Pubitemid 44000257)
40. Kadariya Y, Yin B, Tang B, et al. Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma. Cancer Res. 2009;69(14):5961-5969.
41. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805-812. (Pubitemid 350002880)
42. Copie-Bergman C, Gaulard P, Leroy K, et al. An Immuno-FISH index predicts survival in diffuse large B-cell lymphoma patients treated with R-CHOP: a GELA study. J Clin Oncol. 2009;27(33):5573-5579.
43. Alizadeh AA, Gentles AJ, Lossos IS, Levy R. Molecular outcome prediction in diffuse large-B-cell lymphoma. N Engl J Med. 2009;360(26):2794-2795.
44. Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2008;111(12):5509-5514.
45. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828-1837.